Treatment principles in the management of autoimmune myasthenia gravis

David P Richman, Mark A. Agius

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the post-synaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.

Original languageEnglish (US)
Pages (from-to)457-472
Number of pages16
JournalAnnals of the New York Academy of Sciences
Volume998
DOIs
StatePublished - 2003

Fingerprint

Myasthenia Gravis
Cholinergic Receptors
T-cells
Antibodies
Immune system
Cholinesterase Inhibitors
Nicotinic Receptors
Pathogens
Immunosuppressive Agents
Synaptic Membranes
Acetylcholine
Therapeutics
Critical Care
Autoimmunity
Autoimmune Diseases
Cost-Benefit Analysis
Membranes
Antigens
Immune System
T-Lymphocytes

Keywords

  • Acetylcholine receptor
  • Acetylcholinesterase
  • Autoimmune
  • Immunosuppression
  • Intravenous immunoglobulln
  • Myasthenia gravis
  • Neuromuscular junction
  • Plasma exchange
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Treatment principles in the management of autoimmune myasthenia gravis. / Richman, David P; Agius, Mark A.

In: Annals of the New York Academy of Sciences, Vol. 998, 2003, p. 457-472.

Research output: Contribution to journalArticle

@article{b6650b5c5512423b8f344632b8d4ce7d,
title = "Treatment principles in the management of autoimmune myasthenia gravis",
abstract = "The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the post-synaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.",
keywords = "Acetylcholine receptor, Acetylcholinesterase, Autoimmune, Immunosuppression, Intravenous immunoglobulln, Myasthenia gravis, Neuromuscular junction, Plasma exchange, Treatment",
author = "Richman, {David P} and Agius, {Mark A.}",
year = "2003",
doi = "10.1196/annals.1254.060",
language = "English (US)",
volume = "998",
pages = "457--472",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Treatment principles in the management of autoimmune myasthenia gravis

AU - Richman, David P

AU - Agius, Mark A.

PY - 2003

Y1 - 2003

N2 - The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the post-synaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.

AB - The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the post-synaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.

KW - Acetylcholine receptor

KW - Acetylcholinesterase

KW - Autoimmune

KW - Immunosuppression

KW - Intravenous immunoglobulln

KW - Myasthenia gravis

KW - Neuromuscular junction

KW - Plasma exchange

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0141838992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141838992&partnerID=8YFLogxK

U2 - 10.1196/annals.1254.060

DO - 10.1196/annals.1254.060

M3 - Article

C2 - 14592915

AN - SCOPUS:0141838992

VL - 998

SP - 457

EP - 472

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -